Clinical trial · Interventional
Study of BMS-833923 in Two Specific Patients With Basal Cell Nevus Syndrome
Extension Protocol of BMS-833923 in Subjects With Basal Cell Nevus Syndrome
NCT02100371CI-TRIAL-00028550completedN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This is an extension study of Protocol CA194002 to allow 2 specific participants with basal cell nevus syndrome in the CA194002 study at Princess Margaret Cancer Centre who are still benefitting from the study drug BMS-833923 to continue receiving the study drug. This study will continue to evaluate the safety and tolerability of BMS-833923 in these participants.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Basal Cell Nevus Syndrome | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| BMS-833923 | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- BMS-833923
- description
- BMS-833923, by mouth, at the dose and schedule administered while enrolled in CA194002.
- interventionNames
- Drug: BMS-833923
Primary outcomes (1)
- measure
- Frequency of side effects experienced per participant
- timeFrame
- From date of first study drug dose taken for this study until participant discontinuation, assessed up to 5 years
Secondary outcomes (1)
- measure
- Length of time participants' disease does not worsen
- timeFrame
- From date of first study drug dose taken for this study until the date of first documented progression or date of death from any cause, whichever comes first, accessed up to 5 years
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Signed consent * Two specific study participants enrolled on protocol CA194002 at Princess Margaret Cancer Centre and remain on BMS-833923 at the time of study entry * Women, age 18 years and above * Agree to use methods to prevent pregnancy, not pregnant or breastfeeding Exclusion Criteria: * Known symptomatic brain metastasis * A serious uncontrolled medical disorder or active infection, which would impair the ability of the patient to receive protocol therapy * Gastrointestinal disease or surgery that could impact the absorption of study drug * Inability to swallow oral medication * Inability to be venipunctured and/or tolerate venous access * Uncontrolled or significant cardiovascular * Any other medical, psychiatric and/or social reason * Have HIV, HepB, or HepC * Exposure to immunosuppressants and immunotherapy concurrently with study treatment and up to 3 months * Acceptable physical and laboratory test findings * History of allergy to compounds chemically-related
References
Publications (0)
Data not yet available
No reference posted for this study.